A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.

Trial Details

NCT ID

NCT06525220

Phase

PHASE3

Sponsor

Merus B.V.

Status

RECRUITING

Cancer Type

Head and Neck Cancer

Interventions

Petosemtamab
Pembrolizumab

Locations (sample)

Mobile, Alabama, United States|30.69436,-88.04305
La Jolla, California, United States|32.84727,-117.2742
Los Angeles, California, United States|34.05223,-118.24368
Palo Alto, California, United States|37.44188,-122.14302
Newark, Delaware, United States|39.68372,-75.74966

Key Eligibility Criteria

Signed ICF before initiation of any study procedures
Age ≥ 18 years at signing of ICF
Histologically confirmed HNSCC with evidence of metastatic or locally recurrent disease not amenable to local therapy with curative intent.
The eligible HNSCC primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →